Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden.
Kirk GealeIngrid LindbergEmma C PaulssonE Christina M WennerströmAnna TjärnlundWim NoelDana EnkussonElke TheanderPublished in: Rheumatology advances in practice (2020)
Ustekinumab exhibits a favourable treatment persistency profile relative to adalimumab overall and across lines of treatment. The performance of secukinumab is dependent on biologic experience. Persistence and risk factors for non-persistence should be accounted for when determining an optimal treatment plan for patients.